Context Therapeutics (CNTX) Stock Price, News & Analysis

Company Overview

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies. The company’s development strategy integrates translational science, rigorous patient selection and adaptive trial design, aiming to streamline pathways to regulatory review. Through these efforts, Context Therapeutics seeks to establish proof of concept across multiple indications before pursuing broader commercialization alliances.

Headquartered in the United States, Context Therapeutics conducts its clinical research primarily in North America while laying the groundwork for potential global expansion. The company’s leadership team combines industry veterans in drug development with specialists in oncology and translational medicine. Together, they guide Context Therapeutics as it advances novel candidates through clinical milestones, with the goal of delivering targeted treatment options to patients with high unmet medical need.

Key Stats

• Today's Range: $1.09 to $1.28
• 50-Day Range: $0.68 to $1.21
• 52-Week Range: $0.49 to $2.59
• Volume: 449,110 shs
• Average Volume: 242,905 shs
• Market Capitalization: $101.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.20
• Consensus Rating: Moderate Buy

Context Therapeutics Stock Analysis - MarketRank™

Context Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 315th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Context Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Context Therapeutics has a consensus price target of $5.20, representing about 360.2% upside from its current price of $1.13.

Amount of Analyst Coverage

Context Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Context Therapeutics are expected to grow in the coming year, from ($0.51) to ($0.31) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Context Therapeutics is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Context Therapeutics is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Context Therapeutics has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.86% of the float of Context Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Context Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Context Therapeutics has recently decreased by 2.72%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Context Therapeutics does not currently pay a dividend.

Dividend Growth

Context Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.86% of the float of Context Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Context Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Context Therapeutics has recently decreased by 2.72%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.17

News Sentiment

Context Therapeutics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Context Therapeutics this week, compared to 2 articles on an average week.

Search Interest

17 people have searched for CNTX on MarketBeat in the last 30 days. This is an increase of 183% compared to the previous 30 days.

MarketBeat Follows

4 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Context Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.04% of the stock of Context Therapeutics is held by insiders.

Percentage Held by Institutions

Only 14.03% of the stock of Context Therapeutics is held by institutions.

CNTX Stock Analysis - Frequently Asked Questions

How have CNTX shares performed this year?

Context Therapeutics' stock was trading at $1.05 at the beginning of the year. Since then, CNTX shares have increased by 7.6% and is now trading at $1.13.

How were Context Therapeutics' earnings last quarter?

Context Therapeutics Inc. (NASDAQ:CNTX) released its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.03.

When did Context Therapeutics IPO?

Context Therapeutics (CNTX) raised $25 million in an IPO on Wednesday, October 20th 2021. The company issued 5,000,000 shares at a price of $5.00 per share.

How do I buy shares of Context Therapeutics?

Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Context Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Context Therapeutics investors own include NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Celestica (CLS).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 10/07/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CNTX
• CIK: 1842952
• Web: www.contexttherapeutics.com
• Phone: 267-225-7416
• Fax: N/A
• Employees: 7
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Context Therapeutics: $5.20
• High Price Target: $9.00
• Low Price Target: $4.00
• Potential Upside/Downside: +354.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.73 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -38.80%
• Return on Assets: -37.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.09
• Quick Ratio: 19.09

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.27 per share
• Price / Book: 0.90

Miscellaneous

• Outstanding Shares: 89,700,000
• Free Float: 86,977,000
• Market Cap: $102.71 million
• Optionable: Not Optionable
• Beta: 1.93